Repros in the News
To receive Press Releases via email, Click Here.
10/30/2009 - 06:59 AM
Repros Therapeutics Announces Settlement with Major Creditors
10/28/2009 - 08:01 PM
Repros Therapeutics Announces Amendment of NIH Proellex® License
10/08/2009 - 09:45 AM
Repros Therapeutics Inc. Announces Financing
10/06/2009 - 09:00 PM
Repros Reports Androxal® Restores Normal Sperm Counts While Increasing Testosterone Levels in Hypogonadal Men
09/29/2009 - 06:30 AM
Repros Therapeutics Inc. Provides Update on Proellex
09/21/2009 - 08:00 AM
Repros Therapeutics Inc. Receives Additional NASDAQ Delisting Notice
09/08/2009 - 08:03 AM
Repros Therapeutics Inc. Announces Financing
08/17/2009 - 06:00 AM
Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update
08/11/2009 - 06:00 AM
Repros Announces Class Action Lawsuit Filed Against It and Certain of Its Officers and Directors, and Also Announces Receipt of Notice from NASDAQ of Non-Compliance with Listing Standards
08/06/2009 - 08:17 PM
Repros Therapeutics Inc. Announces That United States Food and Drug Administration Places Proellex® On Clinical Hold
08/03/2009 - 06:00 AM
Repros Therapeutics Inc. Suspends Dosing of Proellex® and Provides Update on Financial Status
07/23/2009 - 06:00 AM
Repros Therapeutics Inc. Provides Clarification on Increased Liver Enzymes at Highest Dose in Proellex® Clinical Program
07/08/2009 - 06:00 AM
Repros Therapeutics Inc. Announces Amendment to NIH License Agreement
07/07/2009 - 06:00 AM
Repros Therapeutics Inc. Provides Additional Information on Proellex® Clinical Program
07/01/2009 - 06:00 AM
Repros Therapeutics Inc. Provides Update for Proellex® Clinical Program
06/05/2009 - 06:00 AM
Repros Therapeutics Inc. Establishes Scientific Advisory Board
05/11/2009 - 06:00 AM
Repros Therapeutics Inc. Reports First Quarter 2009 Financial Results and Provides Clinical Program Update
04/17/2009 - 06:00 AM
Repros Therapeutics Inc. Board Nominates Dr. Stephen Howell to Its Board of Directors
03/20/2009 - 12:15 PM
Repros Announces 2009 Annual Shareholders' Meeting
03/16/2009 - 06:00 AM
Repros Therapeutics Inc. Reports Fourth Quarter and Year End 2008 Financial Results
03/12/2009 - 04:49 PM
Repros to Report Fourth Quarter and Full Year 2008 Financial Results on March 16, 2009
02/23/2009 - 06:00 AM
Repros Therapeutics Announces Appointment of Dr. Paul Lammers as President
02/03/2009 - 06:00 AM
Repros Presentation to Be Webcast from the 11th Annual Bio/CEO & Investor Conference and the Roth 21st Annual OC Growth Stock Conference
01/27/2009 - 06:00 AM
Repros Therapeutics Inc. Announces Information In Compliance With NASDAQ Marketplace Rule 4350
01/12/2009 - 06:00 AM
Repros Therapeutics Inc. Announces That Proellex Significantly Reduced Pain in a U.S. Phase 2 Clinical Trial in Women with Moderate to Severe Endometriosis
12/22/2008 - 01:15 PM
Repros Therapeutics Inc. Board of Directors Elects Mark Lappe of Efficacy Capital as Its Chairman of the Board
11/10/2008 - 05:10 PM
Repros Therapeutics Inc. Files Shelf Registration
11/10/2008 - 06:00 AM
Repros Therapeutics Inc. Reports Third Quarter 2008 Financial Results
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax